agent-framework-durabletask

v1.0.0b260521 suspicious
4.0
Medium Risk

Durable Task integration for Microsoft Agent Framework.

🤖 AI Analysis

Final verdict: SUSPICIOUS

The package has low risks for network, shell, obfuscation, and credential issues. However, the missing maintainer's author name and potential inactivity suggest caution and further investigation.

  • Missing maintainer's author name
  • Potential inactivity of the maintainer
Per-check LLM notes
  • Network: No network calls detected, which is normal if the package does not require external communication.
  • Shell: No shell execution detected, indicating the package does not execute system commands.
  • Obfuscation: No obfuscation patterns detected, indicating low risk.
  • Credentials: No credential harvesting patterns detected, indicating low risk.
  • Metadata: The maintainer's author name is missing and appears to be new or inactive, which raises some suspicion but does not conclusively indicate malice.

🔬 Heuristic Checks

✓ Outbound Network Calls

No suspicious network call patterns found

✓ Code Obfuscation

No obfuscation patterns detected

✓ Shell / Subprocess Execution

No shell execution patterns detected

✓ Credential Harvesting

No credential harvesting patterns detected

✓ Typosquatting

No typosquatting candidates detected

✓ Registered Email Domain

Email domain looks legitimate: microsoft.com>

✓ Suspicious Page Links

All external links appear legitimate

✓ Git Repository History

Repository microsoft/agent-framework appears legitimate

⚠ Maintainer History score 4.0

2 maintainer concern(s) found

  • Author name is missing or very short
  • Author "" appears to have only 1 package on PyPI (new or inactive account)
✓ Known CVE Vulnerabilities

No known vulnerabilities found in OSV database.

💡 AI App Starter Prompt

Use this prompt to build a project with agent-framework-durabletask
Build a simple Python application using the agent-framework-durabletask package to demonstrate its core features.

💬 Discussion Feed

Leave a comment

No discussion yet. Be the first to share your thoughts!